81778-07-6

Basic information

• Product Name: 4，4-dimethyl isoxazolidin-3-one
• Synonyms: 4，4-dimethyl isoxazolidin-3-one;4,4-Dimethyl-1,2-oxazolidin-3-one;3-Isoxazolidinone,4,4-dimethyl-
• CAS NO: 81778-07-6
• Molecular Formula: C₅H₉NO₂
• Molecular Weight: 115.13046
• Mol File: 81778-07-6.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• Density: 1.039 g/cm³
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4，4-dimethyl isoxazolidin-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4，4-dimethyl isoxazolidin-3-one(81778-07-6)
• EPA Substance Registry System: 4，4-dimethyl isoxazolidin-3-one(81778-07-6)

Safety Data

• Hazardous Substances Data: 81778-07-6(Hazardous Substances Data)

Usage

Description

4,4-Dimethyl isoxazolidin-3-one, also known as DMI, is a versatile chemical compound that serves as a solvent and a precursor in the production of pharmaceuticals and agricultural products. It is characterized by its stability, colorless appearance, and slight bitter taste, with solubility in water and most organic solvents.

Uses

Used in Chemical Synthesis:
4,4-Dimethyl isoxazolidin-3-one is used as a reaction intermediate for the synthesis of various pharmaceutical compounds, contributing to the development of new medications.
Used in Pesticide Formulation:
In the agricultural industry, 4,4-dimethyl isoxazolidin-3-one is used as a solvent in the formulation of pesticides, herbicides, and fungicides, enhancing the effectiveness of these products.
Used in Medical Research:
DMI has been studied for its potential use in the treatment of various medical conditions, such as cancer and central nervous system disorders, indicating its possible role in pharmaceutical research and development.
However, it is crucial to handle 4,4-dimethyl isoxazolidin-3-one with care due to its toxic nature when ingested, inhaled, or absorbed through the skin, emphasizing the need for proper safety measures during its use.

Upstream product

• 21491-96-3 methyl 3-chloro-2,2-dimethylpropionate 
• 4300-97-4 3-Chloropivaloyl chloride 
• 81777-89-1 clomazone 
• 1135686-00-8 C₁₄H₂₀FN₃O₇ 
• 81778-06-5 3-chloro-N-hydroxy-2,2-dimethylpropionamide 

Downstream Products

• 124693-87-4 2-(2-chlorobenzylideneaminooxymethyl)-2-methylpropanoic acid 
• 100282-08-4 2-[2-chloro-4-(methoxycarbonylamino)phenyl]methyl-4,4-dimethyl-3-isoxazolidinone 
• 81777-89-1 clomazone 
• 81777-95-9 2-[(2,4-dichlorophenyl)methyl]-4,4′-dimethyl-3-isoxazolidinone 

Relevant articles and documents

Purification method of intermediate 4,4-dimethyl isoxazole-3-ketone

The invention discloses a purification method of an intermediate 4,4-dimethyl isoxazole-3-one, which comprises the following steps: washing a 4,4-dimethyl isoxazole-3-one reaction solution with pure water until the pH value of the oil phase of the reaction solution is 7.5-9.0, dissolving with alcohol, distilling, refluxing, acidifying, crystallizing and filtering to obtain the solid 4,4-dimethyl isoxazole-3-one with a purity of 99.5% or above. The purification process is simple, the post-treatment is highly operable, the key technical problems of low product purity, difficulty in refining andinfluence on the purity of the subsequent product clomazone in the original 4,4-dimethyl isoxazole-3-ketone preparation technology are solved, and the purification process conforms to the concept of green economic cycle.

Low-temperature synthesis process of clomazone

The invention discloses a low-temperature synthesis process of clomazone. The low-temperature synthesis process of the clomazone comprises condensation reaction, cyclization reaction, synthesis reaction and configuration conversion. The low-temperature synthesis process of the clomazone disclosed in the invention starts from analyzing side reaction products, determines the chemical composition ofimpurities, and reduces the amount of the impurities by optimizing process parameters, finding high-efficiency catalysts and controlling side reactions; then, through chemical treatment on the produced isomers, part of the isomers are converted into the product, and part of irreversible by-products are converted into high-boiling-point polymer compounds through reaction, so that the clomazone product is easy to separate; finally, the clomazone product is purified through physical methods to obtain the clomazone with a purity greater than 97%.

PROCESS FOR PREPARING CLOMAZONE, NOVEL FORM AND USE OF THE SAME

A process for preparing clomazone is provided,the process comprising reacting 4,4-dimethyl-3-isoxazolidinone with 2-chlorobenzyl chloride in an aqueous medium in the presence of a base, in particular an alkali metal hydroxide. A method for preparing clomazone is also disclosed, the method comprising (a) crystallizing clomazone from solution in an organic solvent; and (b) isolating the resulting crystals. N-benzene is a particularly suitable solvent. Further, there is provided Form I crystalline 2-[(2-chlorophenyl)methyl]-4,4-dimethyl-3-isoxazolidinone (clomazone), wherein the polymorph Form I is characterized by at least one of the following properties : (i) an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2θ(+/-0.20° θ) at one or more of the following positions : about 10.63, 16.07, 18.08, 19.11, 19.34, 21.20, 24.78 and 28.80; and (ii) an infrared (IR) spectrum having a characteristic peak : at about 2967 and 2870 cm-1.